ZA928162B - Antibodies in immunosuppression. - Google Patents

Antibodies in immunosuppression.

Info

Publication number
ZA928162B
ZA928162B ZA928162A ZA928162A ZA928162B ZA 928162 B ZA928162 B ZA 928162B ZA 928162 A ZA928162 A ZA 928162A ZA 928162 A ZA928162 A ZA 928162A ZA 928162 B ZA928162 B ZA 928162B
Authority
ZA
South Africa
Prior art keywords
immunosuppression
antibodies
vcd44
preparations
relates
Prior art date
Application number
ZA928162A
Other languages
English (en)
Inventor
Margot Zoeller
Peter Herrlich
Helmut Ponta
Original Assignee
Kernforschungsz Karlsruhe
Deutsches Krebsforsch
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kernforschungsz Karlsruhe, Deutsches Krebsforsch, Boehringer Ingelheim Int filed Critical Kernforschungsz Karlsruhe
Publication of ZA928162B publication Critical patent/ZA928162B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA928162A 1991-10-23 1992-10-22 Antibodies in immunosuppression. ZA928162B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4134982A DE4134982A1 (de) 1991-10-23 1991-10-23 Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression

Publications (1)

Publication Number Publication Date
ZA928162B true ZA928162B (en) 1993-05-05

Family

ID=6443260

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA928162A ZA928162B (en) 1991-10-23 1992-10-22 Antibodies in immunosuppression.

Country Status (17)

Country Link
US (1) US5951982A (fr)
EP (1) EP0538754B1 (fr)
JP (1) JPH05310596A (fr)
KR (1) KR100252620B1 (fr)
AT (1) ATE162079T1 (fr)
AU (1) AU659687B2 (fr)
CA (1) CA2081150C (fr)
DE (2) DE4134982A1 (fr)
DK (1) DK0538754T3 (fr)
ES (1) ES2111031T3 (fr)
GR (1) GR3026526T3 (fr)
HU (1) HU216020B (fr)
IL (1) IL103510A0 (fr)
NO (1) NO311965B1 (fr)
NZ (1) NZ244851A (fr)
TW (1) TW273514B (fr)
ZA (1) ZA928162B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589458A (en) * 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
ES2110764T3 (es) * 1993-06-18 1998-02-16 Biotie Therapies Oy Composiciones y metodos de diagnostico empleando anticuerpos monoclonales contra la cd44v6.
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
DE4431297A1 (de) * 1994-09-02 1996-03-07 Boehringer Ingelheim Int Monoklonaler Antikörper gegen CD44v6
DE19540515C1 (de) * 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
AU1672097A (en) * 1996-02-15 1997-09-02 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
DE19652815C2 (de) * 1996-12-18 1999-11-11 Karlsruhe Forschzent Mittel zur Identifizierung und Therapie metastasierender Tumore
DE19653607A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
IL121656A0 (en) * 1997-08-29 1998-02-08 Yissum Res Dev Co Diagnosis prevention and treatment of diabetes
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
WO2004024750A2 (fr) * 2002-09-13 2004-03-25 Dyax Corporation Ligands liant cd44
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
WO2005087264A1 (fr) * 2004-03-17 2005-09-22 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Ciblage de cd44 destine a reduire/prevenir des lesions par ischemie-reperfusion
EP2267030A1 (fr) 2005-08-25 2010-12-29 Repair Technologies, Inc. Dispositifs, compositions et méthodes de protection et de réparation de cellules et de tissus
US8940871B2 (en) 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
WO2010058396A1 (fr) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anticorps anti-cd44vra et procédés diagnostiques et thérapeutiques l'utilisant
EP3495000A1 (fr) 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Procédés et kits pour le diagnostic du cancer et la prédiction d'une valeur thérapeutique
CA3040276A1 (fr) 2009-12-02 2011-06-09 Imaginab, Inc. Minobodies j591 et cys-diabodies pour le ciblage de l'antigene membranaire specifique de la prostate humaine (psma), et procedes d'utilisation
DK2886126T3 (en) 2013-12-23 2017-09-18 Exchange Imaging Tech Gmbh Nanoparticle conjugated to CD44-binding peptides
BR112017000710B1 (pt) 2014-07-15 2024-02-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Polipeptídeo isolado, composição de matéria, e, uso do polipeptídeo isolado ou da composição da matéria
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
WO2018147960A1 (fr) 2017-02-08 2018-08-16 Imaginab, Inc. Séquences d'extension pour dianticorps
US11313243B2 (en) 2018-07-12 2022-04-26 Rolls-Royce North American Technologies, Inc. Non-continuous abradable coatings

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114478T1 (de) * 1987-08-11 1994-12-15 Univ Leland Stanford Junior Verfahren zur kontrolle der leukozyten- extravasation.
DE4014510A1 (de) * 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
CA2059824A1 (fr) * 1991-02-26 1992-08-27 Thomas M. Aune Hybridomes et anticorps monoclonaux qui inhibent la proliferation des lymphocytes t stimules anti-cd3
ES2110764T3 (es) * 1993-06-18 1998-02-16 Biotie Therapies Oy Composiciones y metodos de diagnostico empleando anticuerpos monoclonales contra la cd44v6.

Also Published As

Publication number Publication date
EP0538754A3 (en) 1994-05-25
DK0538754T3 (da) 1998-03-30
JPH05310596A (ja) 1993-11-22
AU659687B2 (en) 1995-05-25
NZ244851A (en) 1997-07-27
GR3026526T3 (en) 1998-07-31
NO924103D0 (no) 1992-10-22
CA2081150A1 (fr) 1993-04-24
NO311965B1 (no) 2002-02-25
NO924103L (no) 1993-04-26
CA2081150C (fr) 2001-04-10
EP0538754B1 (fr) 1998-01-14
AU2724492A (en) 1993-04-29
KR100252620B1 (ko) 2000-09-01
ATE162079T1 (de) 1998-01-15
US5951982A (en) 1999-09-14
HUT63063A (en) 1993-07-28
HU216020B (hu) 1999-04-28
ES2111031T3 (es) 1998-03-01
EP0538754A2 (fr) 1993-04-28
TW273514B (fr) 1996-04-01
IL103510A0 (en) 1993-03-15
DE4134982A1 (de) 1993-04-29
KR930007460A (ko) 1993-05-20
DE59209129D1 (de) 1998-02-19

Similar Documents

Publication Publication Date Title
ZA928162B (en) Antibodies in immunosuppression.
GB9415380D0 (en) Recombinant antibodies specific for tnf-
HU9200884D0 (en) Gele preparations
EP0676966A4 (fr) Anticorps diriges contre les epitopes associes par liaison.
HK1005013A1 (en) Antihypertensive hyperimmune milk
EP0329961A3 (en) Use of 2-oxo-pyrrolidine-1-acetamide for the determination of glomerular filtration rate in humans
GB9011589D0 (en) Amino bicyclic compounds
AU7796291A (en) High affinity antibodies to small peptides
GB9027728D0 (en) Novel protein
GB9002830D0 (en) L.c.cyanoalkenes & alkenes
IT1246852B (it) Corpo composito per rubinetti
IE840226L (en) Cosmetic
ITBS920112A1 (it) Corpo composito per rubinetti
ZA929176B (en) Aminoalkyl-substituted 5,6-dihydro-dibenz(b e)azepine-6,11-dione-11-oximes.
DE69534740D1 (en) Analoge des thymosin alpha 1
AU195P (en) GOLDEN FRIENDSHIP Rosa hybrid
AU165P (en) CECILIA Rosa hybrid
GB9301220D0 (en) Protein composition
GB9211317D0 (en) Novel antigens
GB9219104D0 (en) Cognition enhancing agents
GB9216477D0 (en) Cognition enhancing agents
AU116689S (en) Hand puppet
ITBS910066U1 (it) Corpo composito per rubinetti
ITBS910074A1 (it) Corpo composito per rubinetti
GB9127033D0 (en) Hand-held puppet